Burning Rock Biotech Ltd income statement

In fiscal 2025, Burning Rock Biotech Ltd reported revenue of $75.1m, up 4.7% on the year before, operating income of −$7.6m (a -10.2% margin) and net income of −$7.7m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Burning Rock Biotech Ltd: income statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	32	55	62	79	84	76	72	75
Cost of revenue	11	16	17	22	27	25	21	19
Gross profit	20	40	46	56	57	51	50	56
Research and development	16	23	38	57	63	49	32	23
Selling and marketing	16	22	24	47	55	35	27	23
General and administrative	13	19	43	76	85	62	36	18
Operating income	−24	−24	−60	−124	−146	−95	−50	−8
Interest expense	3	1	0	0	—	—	—	—
Net interest income	—	—	−0	−0	0	0	0	−0
Income before tax	−27	−24	−59	−123	−144	−92	−47	−7
Income tax	0	0	0	0	0	0	1	0
Net income	−27	−24	−59	−124	−145	−92	−48	−8
Diluted shares (average)	2m	2m	—	—	—	—	—	—
EBITDA	−21	−20	−55	−116	−128	−76	−42	−5

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BNR vs CDXS BNR vs XGN BNR vs PSNL BNR vs HBIO

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Burning Rock Biotech Ltd's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Burning Rock Biotech Ltd.